Premium
The Anti‐ HIV Microbicide Candidate RC ‐101 Inhibits Pathogenic Vaginal Bacteria Without Harming Endogenous Flora or Mucosa
Author(s) -
Eade Colleen R.,
Cole Amy L.,
Diaz Camila,
Rohan Lisa C.,
Parniak Michael A.,
Marx Preston,
Tarwater Patrick M.,
Gupta Phalguni,
Cole Alexander M.
Publication year - 2013
Publication title -
american journal of reproductive immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.071
H-Index - 97
eISSN - 1600-0897
pISSN - 1046-7408
DOI - 10.1111/aji.12036
Subject(s) - microbicide , microbicides for sexually transmitted diseases , vaginal microbicide , vaginal flora , vagina , microbiology and biotechnology , pathogenic bacteria , bacteria , vaginitis , biology , medicine , immunology , human immunodeficiency virus (hiv) , bacterial vaginosis , population , gynecology , surgery , genetics , environmental health , health services
Problem Vaginal microbicides represent a promising approach for preventing heterosexual HIV transmission. However, preclinical evaluation should be conducted to ensure that microbicides will be safe for human cells and healthy microflora of the female reproductive tract. One microbicide candidate, RC ‐101, has been effective and well tolerated in preliminary cell culture and macaque models. However, the effect of RC ‐101 on primary vaginal tissues and resident vaginal microflora requires further evaluation. Method of study We treated primary vaginal tissues and vaginal bacteria, both pathogenic and commensal, with RC ‐101 to investigate effects of this microbicide. Results RC ‐101 was well tolerated by host tissues, and also by commensal vaginal bacteria. Simultaneously, pathogenic vaginal bacteria, which are known to increase susceptibility to HIV acquisition, were inhibited by RC ‐101. Conclusions By establishing vaginal microflora, the specific antibacterial activity of RC ‐101 may provide a dual mechanism of HIV protection. These findings support advancement of RC ‐101 to clinical trials.